-
S3I-201: A Proportionate Stat3 Overview
2026-10-14
S3I-201, also known as NSC-74859, is described by APExBIO as a small-molecule inhibitor of Stat3 DNA binding and signaling. The product information reports biochemical selectivity over Stat1 and Stat5, interference with Stat3-containing complexes, reduced Stat3 Tyr-705 phosphorylation, suppression of selected Stat3-regulated genes, apoptosis in Stat3-active cells, and tumor growth inhibition in a mouse xenograft model. These claims remain product-description evidence rather than independently verified, identity-matched research findings; key details such as sample sizes, uncertainty estimates, comparator design, and full selectivity profiling are not available.
-
ω-Agatoxin IVA TFA: Reading the Cav2.1 Evidence
2026-10-14
A source-grounded guide to what ω-agatoxin IVA can and cannot show about Cav2.1-dependent GABA release, emphasizing the Singh et al. mouse study, supplier provenance, and evidence limitations.
-
Chemerin, CNQX, and NTS Cardiovascular Signaling
2026-10-13
A source-grounded overview of a 2024 rat study examining how chemerin signaling in the caudal nucleus tractus solitarius influences sympathetic activity and blood pressure, with CNQX used to distinguish AMPA/kainate from NMDA receptor involvement.
-
NF 449 and Platelet P2X1: Evidence and Limits
2026-10-13
NF 449 is a research antagonist used to examine ATP-gated P2X1 signaling in platelets. Evidence from one central 2005 study supports effects on platelet calcium signaling, collagen-induced aggregation and experimental thrombosis, while also showing that selectivity depends on biological context and exposure. These findings do not establish clinical efficacy or safety.
-
Calpeptin, EV Release, and Evidence Boundaries
2026-10-12
Calpeptin is a calpain inhibitor studied as a pharmacological probe of extracellular-vesicle release, while separate supplier-reported findings describe effects in pulmonary fibrosis models. The evidence supports mechanistic investigation, but it does not establish a selective calpain mechanism, clinical efficacy, or direct transferability between triple-negative breast cancer and pulmonary fibrosis.
-
Documented Scope of an HRP Anti-Rabbit IgG Antibody
2026-10-12
APExBIO lists SKU K1223 as an affinity-purified, polyclonal goat anti-rabbit IgG antibody recognizing heavy and light chains and conjugated to horseradish peroxidase. With no matched research paper available, the evidence supports only a documented product identity and broad conceptual use in rabbit-IgG detection workflows, not claims about comparative performance, clinical relevance, or assay outcomes.
-
Coelenterazine: Evidence Gaps in ROS Comparisons
2026-10-11
The supplied evidence describes Coelenterazine as a luminescent enzyme substrate with proposed reporter and reactive oxygen species applications, but it does not provide a head-to-head validation against alternative ROS readouts. Greenwood et al. offer relevant biological context for AVP and kidney signaling, not evidence that Coelenterazine measures or explains that pathway.
-
Z17 and Astrocyte Amyloid Clearance in Alzheimer’s
2026-10-10
The 2026 International Journal of Biological Macromolecules study reports Z17 as a direct CHI3L1 inhibitor that counteracts inflammatory signaling and restores several astrocyte functions relevant to amyloid handling. Its evidence is compelling at the cellular, mechanistic level, but remains preclinical: the work does not establish plaque clearance, therapeutic efficacy, or safety in animal models or patients.
-
Erastin and Ferroptosis: Evidence, Context, Limits
2026-10-10
Erastin is a widely used ferroptosis inducer for studying cystine metabolism, redox control, iron dependence, and genotype-linked tumor vulnerabilities. This overview compares foundational Erastin research with a 2026 study of realgar transforming solution in NB4 leukemia cells, emphasizing evidence strength, provenance, and limits of interpretation.
-
Bromodomain Inhibitor (+)-JQ1: Evidence Overview
2026-10-09
A source-grounded overview of (+)-JQ1 examines BET biology, BRD4–RAC1 signaling in breast cancer, reported apoptosis and inflammatory findings, conceptual applications, and the limits of preclinical evidence.
-
Dihydroartemisinin: Evidence, Uses and Limitations
2026-10-09
Dihydroartemisinin is a defined artemisinin derivative with established relevance to malaria research, but the supplied evidence does not directly support every claimed application. This overview separates catalog information from primary research, compares DHA claims with a recent cabamiquine pharmacodynamic study, and outlines evidence strength, translational boundaries, and unanswered questions.
-
Parthenolide, NLRP3, and Gout-Like Inflammation
2026-10-08
A 2026 study reports that parthenolide reduced MSU-associated inflammation, influenced NLRP3 inflammasome activation, and improved biochemical features of experimental hyperuricemia. Its main contribution is a cross-model view connecting inflammatory signaling, phagocytic behavior, uric acid metabolism, and renal injury, although the findings remain preclinical.
-
Phosbind Acrylamide: Reading Causal Evidence
2026-10-08
Phosbind Acrylamide enables antibody-independent protein phosphorylation analysis through phosphate-dependent mobility shifts. This article shows how that readout can strengthen, but not independently prove, mechanistic models linking ubiquitination, autophagy, and fungal pathogenicity.
-
Gastric Cancer Assembloids: What the Study Shows
2026-10-07
Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine tumor organoids with matched stromal cell subpopulations. Their findings show that stromal context can reshape gene expression and drug sensitivity, supporting more physiologically relevant preclinical oncology research while also defining important limits for translation.
-
Indole-3-pyruvic Acid: Evidence and Research Context
2026-10-07
Indole-3-pyruvic acid (IPA) is a tryptophan metabolite with distinct roles in auxin biology and AhR-linked immune research. Current evidence supports IPA as a mechanistic research compound, while animal findings and vendor-reported cancer effects remain insufficient for clinical extrapolation.